IDNA

iShares Genomics Immunology and Healthcare ETF
*Unless otherwise stated, data provided by FactSet.

IDNA Fund Description

IDNA tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering.

IDNA Factset Analytics Insight

IDNA holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. In addition to these industry screens, companies must also meet certain size and liquidity measures for index eligibility. The underlying index then assigns a “Relationship Keyword Score” to each of the eligible companies using the FactSet Supply Chain Relationships database in search for keywords related to ‘Genomics and Immuno Biopharmaceutical’ products and technologies. The top 50 names with the highest scores are included in the index. Holdings are weighted by market-cap and are constrained such that no individual security exceeds 4% weight of the portfolio. The index rebalances semi-annually.

IDNA MSCI ESG Analytics Insight

iShares Genomics Immunology and Healthcare ETF has an MSCI ESG Fund Rating of BB based on a score of 5.40 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. iShares Genomics Immunology and Healthcare ETF ranks in the 31st percentile within its peer group and in the 42nd percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

PERFORMANCE [as of 11/29/21] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
IDNA -4.85% -11.00% 3.35% 13.40% -- -- --
IDNA (NAV) -4.44% -11.83% 3.01% 8.33% -- -- --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

IDNA Summary Data

Blackrock
iShares
06/11/19
Open-Ended Fund
0.47%
$346.50M
$2.82M
0.12%

IDNA Portfolio Data

$35.48B
-95.16
4.97
0.19%
12/13/21
51

IDNA Index Data

NYSE FactSet Global Genomics and Immuno Biopharma Index
Market Cap
Market Cap
N/A

IDNA Portfolio Management

0.47%
--
--
--

IDNA Tax Exposures

20.00% / 39.60%
0.48%
Qualified dividends
No

IDNA Fund Structure

Open-Ended Fund
No
No
-- / --
N/A
N/A
Low
Daily

IDNA Factset Analytics Block Liquidity

As of 11/30/21
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of IDNA. IDNA is rated a 5 out of 5.

IDNA Tradability

59,367
$2.82M
54,095
$2.52M
0.12%
$0.06
0.11%
0.61% / -0.40%
None
74.00%
50,000
1.08
0.03%
0.18%
95
$47.29
5

IDNA Top 10 Holdings[View All]

5.63%
Seagen, Inc. 4.55%
4.39%
49.43%

IDNA Countries


IDNA
Segment Benchmark
70.84%
--
13.64%
--
4.40%
--
4.16%
--
3.43%
--
3.10%
--
0.43%
--

IDNA Regions


IDNA
Segment Benchmark
70.84%
--
22.63%
--
6.53%
--

IDNA Economic Development


IDNA
Segment Benchmark
100.00%
--

IDNA Performance Statistics

--
--
--
--
0.00%
N/A

IDNA MSCI ESG Ratings

5.40 / 10
41.54
30.51
--
--
28.42

IDNA Benchmark Comparison Holdings

51
--
--
0.00%

IDNA Benchmark Comparison Summary


IDNA
Segment Benchmark
51
--
$35.48B
--
-95.16
--
4.97
--
0.46%
--
Medium
High

IDNA Benchmark Comparison Market Cap Size


IDNA
Segment Benchmark
42.29%
--
45.55%
--
11.48%
--
0.68%
--